Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Lucid Diagnostics
(NASDAQ:LUCD)
Intraday
$0.77
0.0869
[12.72%]
After-Hours
$0.77
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$0.77
0.0869
[12.72%]
At close: Apr 29
$0.77
0
[0.00%]
After Hours: 7:05PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Lucid Diagnostics Stock (NASDAQ:LUCD)
Lucid Diagnostics Stock (NASDAQ: LUCD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, April 29, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
4 hours ago
Friday, April 12, 2024
Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
Benzinga Newsdesk
-
Apr 12, 2024, 4:37AM
Wednesday, March 27, 2024
Cantor Fitzgerald Maintains Overweight on Lucid Diagnostics, Lowers Price Target to $3
Benzinga Newsdesk
-
Mar 27, 2024, 10:05AM
Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
Benzinga Newsdesk
-
Mar 27, 2024, 5:20AM
Monday, March 25, 2024
Lucid Diagnostics Q4 EPS $(0.23) Beats $(0.26) Estimate, Sales $1.04M Miss $1.05M Estimate
Happy Mohamed
-
Mar 25, 2024, 5:43PM
Lucid Diagnostics Provides Business Update; Reports Q4 EsoGuard Revenue Of $1.04M, Up 33% Sequentially
Benzinga Newsdesk
-
Mar 25, 2024, 5:33PM
Earnings Scheduled For March 25, 2024
Benzinga Insights
-
Mar 25, 2024, 5:33AM
Friday, March 22, 2024
Earnings Preview: Lucid Diagnostics
Benzinga Insights
-
Mar 22, 2024, 10:01AM
Thursday, March 21, 2024
Lucid Diagnostics Announces Data From The First Prospective Clinical Validation Study Of EsoGuard Esophageal Precancer Testing In A Screening Population
Benzinga Newsdesk
-
Mar 21, 2024, 9:31AM
Wednesday, March 20, 2024
Lucid Diagnostics Announces Multiple Presentations At Digestive Disease Week 2024 Conference
Benzinga Newsdesk
-
Mar 20, 2024, 8:44AM
Monday, February 19, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Feb 19, 2024, 4:30PM
Thursday, January 18, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Jan 18, 2024, 8:05AM
Tuesday, December 12, 2023
Lucid Diagnostics Announces Peer-Reviewed Publication Of Results From Three Clinical Utility Studies; Studies Demonstrate Real-World Clinical Utility Of EsoGuard Testing To Detect Esophageal Precancer
Benzinga Newsdesk
-
Dec 12, 2023, 8:31AM
Monday, December 11, 2023
PAVmed Provides Additional Details For Upcoming Stock Dividend To Shareholders; PAVmed Shareholders As Of January 15, 2024 Will Participate In Distribution Of ~3.3M Shares Of Lucid Common Stock
Benzinga Newsdesk
-
Dec 11, 2023, 9:18AM
Monday, December 04, 2023
PAVmed Shareholders As Of January 15, 2024 Will Participate In Distribution Of ~3.3M Shares Of Lucid Common Stock And Also Announces 1-For-15 Reverse Stock Split
Benzinga Newsdesk
-
Dec 4, 2023, 4:29PM
Tuesday, November 28, 2023
On November 27, 2023, Lucid Diagnostics Received Notice On Approval Of Application To Transfer Listing From Nasdaq Global Market To Nasdaq Capital Market - Filing
Benzinga Newsdesk
-
Nov 28, 2023, 4:36PM
Thursday, November 16, 2023
Lucid Diagnostics Strengthens And Expands Market Access And Direct Contracting Efforts; Shaun M. O'Neil Promoted To Lucid's President And COO
Benzinga Newsdesk
-
Nov 16, 2023, 9:14AM
Tuesday, November 14, 2023
Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2.5
Benzinga Newsdesk
-
Nov 14, 2023, 1:43PM
Monday, November 13, 2023
Lucid Diagnostics Q3 Adj EPS $(0.22) Beats $(0.27) Estimate, Sales $783.00K Beat $780.00K Estimate
Benzinga Newsdesk
-
Nov 13, 2023, 5:54PM
Lucid Diagnostics Q3 EPS $(0.22) Beats $(0.27) Estimate, Sales $783.00K Beat $780.00K Estimate
Benzinga Newsdesk
-
Nov 13, 2023, 5:45PM
Lucid Diagnostics Reports Q3 EsoGuard Revenue Of $783K
Benzinga Newsdesk
-
Nov 13, 2023, 5:44PM
Earnings Scheduled For November 13, 2023
Benzinga Insights
-
Nov 13, 2023, 6:40AM
Friday, November 10, 2023
Earnings Preview For Lucid Diagnostics
Benzinga Insights
-
Nov 10, 2023, 11:02AM
Tuesday, September 26, 2023
Cantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $4 Price Target
Benzinga Newsdesk
-
Sep 26, 2023, 11:45AM
Thursday, September 07, 2023
Lucid Diagnostics Releases Positive Data From First Prospective Clinical Utility Study Of EsoGuard Esophageal Precancer Detection
Benzinga Newsdesk
-
Sep 7, 2023, 9:29AM
Wednesday, September 06, 2023
Lucid Diagnostics Releases Data Demonstrating Clinical Utility Of EsoGuard Esophageal Precancer Detection In Fire Fighters
Happy Mohamed
-
Sep 6, 2023, 9:25AM
Thursday, August 24, 2023
Lucid Diagnostics Executes First Direct Employer Contract To Provide Ancira Auto Group EsoGuard Esophageal Precancer Testing As An Employee Benefit
Happy Mohamed
-
Aug 24, 2023, 9:06AM
Tuesday, August 22, 2023
Cantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $4 Price Target
Benzinga Newsdesk
-
Aug 22, 2023, 11:37AM
Wednesday, August 16, 2023
Cantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $4 Price Target
Benzinga Newsdesk
-
Aug 16, 2023, 9:33AM
Monday, August 14, 2023
Lucid Diagnostics Q2 EPS $(0.27) Beats $(0.32) Estimate, Sales $159.00K Miss $620.00K Estimate
Benzinga Newsdesk
-
Aug 14, 2023, 4:58PM
Earnings Scheduled For August 14, 2023
Benzinga Insights
-
Aug 14, 2023, 6:45AM
Wednesday, July 19, 2023
PAVmed And Lucid Chairman And Chief Executive Officer, Dr. Lishan Aklog, Testifies At U.S. House Of Representatives Energy And Commerce Committee, Hearing On Life-Saving Innovations And Medicare Coverage
Happy Mohamed
-
Jul 19, 2023, 9:14AM
Monday, June 05, 2023
Lucid Diagnostics Launches EsoGuard Mobile Test Unit
Benzinga Newsdesk
-
Jun 5, 2023, 7:16AM
Wednesday, May 17, 2023
Where Lucid Diagnostics Stands With Analysts
Benzinga Insights
-
May 17, 2023, 12:00PM
Cantor Fitzgerald Maintains Overweight on Lucid Diagnostics, Lowers Price Target to $4
Benzinga Newsdesk
-
May 17, 2023, 9:38AM
Needham Maintains Buy on Lucid Diagnostics, Raises Price Target to $2.8
Benzinga Newsdesk
-
May 17, 2023, 4:13AM
Tuesday, May 16, 2023
Lucid Diagnostics Q1 EPS $(0.40) Misses $(0.35) Estimate, Sales $446.00K Beat $220.00K Estimate
Happy Mohamed
-
May 16, 2023, 1:24AM
Monday, May 15, 2023
Earnings Scheduled For May 15, 2023
Benzinga Insights
-
May 15, 2023, 5:32AM
Friday, May 12, 2023
Preview: Lucid Diagnostics's Earnings
Benzinga Insights
-
May 12, 2023, 11:03AM
Thursday, May 11, 2023
Lucid Diagnostics And Collaborators Present New EsoGuard And EsoCheck Data At Digestive Disease Week 2023 Conference
Happy Mohamed
-
May 11, 2023, 8:46AM
Friday, April 21, 2023
Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.6 Price Target
Benzinga Newsdesk
-
Apr 21, 2023, 6:53AM
Tuesday, April 18, 2023
Lucid Diagnostics Reports Publication Of Future Effective Foundational Local Coverage Determination By Medicare Administrative Contractor Noridian Healthcare Solutions
Happy Mohamed
-
Apr 18, 2023, 8:54AM
Friday, March 31, 2023
Watching Lucid Diagnostics; Traders Circulate CMS.gov Link Titled 'MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia'
Benzinga Newsdesk
-
Mar 31, 2023, 1:49PM
Friday, March 24, 2023
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Mar 24, 2023, 9:06AM
Wednesday, March 15, 2023
Lucid Diagnostics Earnings Perspective: Return On Capital Employed
Benzinga Insights
-
Mar 15, 2023, 10:48AM
Tuesday, March 14, 2023
Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2.6
Benzinga Newsdesk
-
Mar 14, 2023, 2:17PM
Lucid Diagnostics Q4 EPS $(0.29) Beats $(0.38) Estimate, Sales $112.00K Miss $340.00K Estimate
Happy Mohamed
-
Mar 14, 2023, 12:56AM
Monday, March 13, 2023
A Preview Of Lucid Diagnostics's Earnings
Benzinga Insights
-
Mar 13, 2023, 12:01PM
Wednesday, January 18, 2023
Why PAVmed Shares Are Falling Today
Sean Torres
-
Jan 18, 2023, 2:18PM
PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs
Vandana Singh
-
Jan 18, 2023, 6:24AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch